by Aptus PM Team | Jan 23, 2024 | Market Updates
When we made the Aptus Compounders sleeve available to advisors in 2018, we never put much thought into the actual strategy name. It just came naturally to us, and we ran with it. We didn’t put much thought into how the name embodied exactly what we were looking to...
by Aptus PM Team | Jan 4, 2024 | Appearances, Market Updates
Investors waded into 2023 with fresh scar tissue after 2022, which was a year worth forgetting as the S&P 500 shed 19% and the Nasdaq 100 dropped 33%. “An imminent recession” in 2023 was the consensus view heading into the year, yet this depressed sentiment has...
by Aptus PM Team | Jan 2, 2024 | Most Read, Process Papers
Drawdown Patrol Investing: Upside Capture Through Downside Protection Our approach is designed to produce what every investor wants, potential for growth and income while defending against their most feared risks. Today’s backdrop requires different thinking; here is...
by Derek Hernquist | Dec 5, 2023 | Market Updates
Given the popularity of our weekly Market in Pictures, we thought it made sense to pick out a few and go into more detail with our PMs. In this edition, Dave and John Luke will spend a few minutes on each of the following: Equal-weighted S&P 500 vs. Cap-weighted...
by David Wagner | Dec 5, 2023 | Equity Case Studies, Equity Research, Research Reports
In today’s report, we’ll be covering Chemed Corporation (“CHE”) – in our opinion, one of the last, great remaining publicly traded conglomerate companies. Conglomerates were in vogue for the majority of the 20th century. They came about because most of the mergers in...
